TrialJournal of managed care & specialty pharmacy2023

Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.

Matthew R Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.